Cardiovascular and Metabolic Sciences Biorepository

June 23, 2026 updated by: Wilson Tang, The Cleveland Clinic
The purpose of the Cardiovascular and Metabolic Sciences Biorepository is to collect and store information and biospecimens (blood, urine, stool, and heart tissue) from patients with and without cardiovascular and metabolic diseases to create a readily available biorepository of samples and related medical health information to expedite future research into the causes and consequences of cardiovascular and metabolic diseases.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Heart disease is the leading cause of death in the United States and other vascular diseases, like stroke, and metabolic diseases, like diabetes, are consistently in the top ten causes of death (CDC, 2024). There is clearly a need for continuing research and innovation into improved diagnosis and treatment of these diseases.

The goal of this biorepository is to provide an easily accessible collection of samples for researchers to utilize. The biorepository will also serve as a place to store residual samples from other cardiovascular disease (CVD) studies for future use, to make the best use of these biospecimen resources.

Study Type

Observational

Enrollment (Estimated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Jennifer Wilcox, BA
  • Phone Number: 216-636-6153
  • Email: kirsopj@ccf.org

Study Contact Backup

  • Name: Valesha Province, MA
  • Phone Number: 216-636-6153
  • Email: provinv@ccf.org

Study Locations

  • United States
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Recruiting
        • Cleveland Clinic Main Campus
        • Principal Investigator:
          • W. H. Wilson Tang, MD
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

We will enroll persons with diagnosed cardiovascular or metabolic disease(s), persons with a family history of cardiovascular and/or metabolic disease(s), and persons without known cardiovascular or metabolic disease(s). The targeted number of participants to be enrolled is indefinite.

Description

Inclusion Criteria:

  • Willing and able to sign the informed consent document

Exclusion Criteria:

  • Chronic anemia (hemoglobin consistently <9 g/L)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Personal History of Cardiovascular or Metabolic Diseases
Persons who have a diagnosis of a cardiovascular or metabolic disease. Examples of cardiovascular diseases are: heart failure, arrhythmias, high cholesterol, coronary artery disease, heart attack, and stroke. Examples of metabolic diseases are: diabetes, metabolic syndrome, and hemochromatosis.
Family History of Cardiovascular or Metabolic Diseases
Persons without a personal diagnosis of any cardiovascular or metabolic disease but with a family history in a first-degree relative of one of those diseases.
Healthy Controls
No personal or family (first-degree relative) history of cardiovascular or metabolic diseases.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of samples enrolled per year
Time Frame: Yearly through study completion (approximately 30 years)
Establish a biorepository of samples (blood, urine, stool, and heart tissue) and related medical health information to support future investigation into cardiovascular and metabolic diseases.
Yearly through study completion (approximately 30 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Cleveland Clinic

Investigators

  • Principal Investigator: W. H. Wilson Tang, MD, The Cleveland Clinic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 18, 2024

Primary Completion (Estimated)

December 31, 2050

Study Completion (Estimated)

December 31, 2050

Study Registration Dates

First Submitted

August 13, 2024

First Submitted That Met QC Criteria

August 15, 2024

First Posted (Actual)

August 19, 2024

Study Record Updates

Last Update Posted (Actual)

June 25, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 24-708

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe